# A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Study · id `cardio:ct-nct05803421` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05803421](<https://clinicaltrials.gov/study/NCT05803421>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05803421

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2749 participants.

## Technical summary

Registry record NCT05803421. Randomized; no masking; primary purpose treatment. Start 2023-04-03 (actual); primary completion 2026-03-16 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2749 participants (enrolled count; ClinicalTrials.gov record NCT05803421, source copy `cardio:ctgov-nct05803421-2026-04-17`, retrieved 2026-10-26)
- Started: 2023-04-03 (actual) (ClinicalTrials.gov record NCT05803421, source copy `cardio:ctgov-nct05803421-2026-04-17`, retrieved 2026-10-26)
- Primary completion: 2026-03-16 (actual) (ClinicalTrials.gov record NCT05803421, source copy `cardio:ctgov-nct05803421-2026-04-17`, retrieved 2026-10-26)
- Completion: 2026-03-16 (actual) (ClinicalTrials.gov record NCT05803421, source copy `cardio:ctgov-nct05803421-2026-04-17`, retrieved 2026-10-26)
- Countries: United States; Argentina; Austria; Brazil; Czechia; Germany; Greece; India; Italy; Mexico; Puerto Rico; Romania; Slovakia; South Korea; Spain; Türkiye (ClinicalTrials.gov record NCT05803421, source copy `cardio:ctgov-nct05803421-2026-04-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05803421-2026-04-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
- Acronym: ACHIEVE-4
- Condition: Type 2 Diabetes
- Condition: Obesity
- Condition: Overweight or Obesity
- Condition: Overweight
- Condition: Cardiovascular Diseases
- Condition: Chronic Kidney Disease
- Intervention (Drug): Orforglipron
- Intervention (Drug): Insulin Glargine
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial (`cardio:pubmed-42815506`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2add84c094d45621f7d560cdb1e09d16d7563e6951676684b140b2b693c7205d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
